

- **Full Name:** Sun-Young Kong
 - **Current Position & Affiliation:** Chief Scientist, Targeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center (NCC)
Faculty, Department of Laboratory Medicine, Hospital, NCC
Professor, Department of Cancer Biomedical Science, NCC-GCSP(Graduate School of Cancer Science and Policy)
 - **Country:** Republic of Korea
-

• Educational Background:

- MD, Ewha Womens University College of Medicine (1997)
- MS, Ewha Womens University Graduate School of Medicine (2001)
- PhD, Sungkyunkwan University Graduate School of Medicine (2005)

• Professional Experience:

- Internship & Residency, Samsung Medical Center (1997-2002)
- Clinical Fellowship, Samsung Medical Center & NCC (2002-2005)
- Faculty, Department of Laboratory Medicine, National Cancer Center (2005-Present)
- Associate Scientist, Hematologic Malignancies Branch, National Cancer Center (2005-2009)
- Senior Scientist, Hematologic Malignancies Branch, National Cancer Center (2009-2012)
- Dana-Farber Cancer Institute (2009-2011)
- Chief, Translational Epidemiology Branch, National Cancer Center (2013-2017)
- Professor, Department of System Cancer Science, Graduate School of Cancer Science & Policy (2014-Present)
- Chief, Translational Research Branch, National Cancer Center (2017)
- Chief, Flow Cytometry Unit, National Cancer Center (2017-2019)
- Chief, Department of Laboratory Medicine, National Cancer Center (2018-2021)

• Professional Organizations:

- Korean Society for Laboratory Medicine (2003-)
- Korean Cancer Association (2006-)
- Korean Society of Hematology (2007-)
- Korean Society of Medical Oncology (2012-)
- Korean Society for Genetic Diagnostics (2013-)
- Korea Genome Organization (2015 -)

• Main Scientific Publications:

1. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study: *Cancers* (2021)
2. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer: *Cancer Science* (2020)
3. Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test: *Cancer Research and Treatment* (2020)
4. Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer: *Cancers* (2019)
5. Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women: *Cancer Science* (2019)
6. Differences in attitudes toward genetic testing among the public, patients, and health-care professionals in Korea: *European journal of human genetics* (2018)
7. Prognostic implications of multiplex detection of KRAS mutations in cell-free DNA from patients with pancreatic ductal adenocarcinoma: *Clinical Chemistry* (2018)
8. Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: *Cancer Research and Treatment* (2018)
9. Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients: *Breast Cancer Research and Treatment* (2017)
10. Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes Among Korean Breast Cancer Patients: *Cancer Research and Treatment* (2016)